On May 20, Acorda announced the discontinuation of the PLUMIAZ development program. For additional details, please click here.
Below is a letter from our CEO, Dr. Ron Cohen, to PLUMIAZ study participants and their families. We would like to thank everyone who invested time, hard work and hope in the PLUMIAZ development program — clinical trial investigators, their staff, care partners, and especially the participants and their families. It would be impossible to make new medicines available without the commitment and sacrifice of each of you.
We are disappointed that this program did not deliver a new therapeutic option for people with seizure clusters, but the learnings from these studies will contribute to greater scientific understanding of novel delivery systems for epilepsy drugs, and will help inform the design and development of new treatments in the future.